Streetbeat News

SXTP

60 Degrees Pharmaceuticals, Inc.

https://60degreespharma.com

Industry

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

60 Degrees Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement as of August 26, 2024, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 7:02 pm

60 Degrees Pharmaceuticals shares are trading higher following the company's announcement of a year-over-year increase in Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:15 pm

HC Wainwright & Co. analyst Edward White has reiterated a Neutral rating on 60 Degrees (NASDAQ:SXTP).

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:41 am

60 Degrees (NASDAQ:SXTP) reported Q2 EPS of $(4.23), a significant improvement from $(16.84) YoY. Sales increased by 109.92% to $124.97K from $59.53K YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 3:15 pm

60 Degrees Pharmaceuticals shares are trading higher after the company announced that it granted the University of Kentucky a right of reference to its new drug application for ARAKODA.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:07 pm

60 Degrees Pharmaceuticals (SXTP) shares have resumed trading.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:04 pm

60 Degrees Pharmaceuticals shares were halted on a circuit breaker due to a significant upward movement, with the stock now up 70.6%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 1:55 pm

60 Degrees Pharma has granted the University of Kentucky the right of reference to its New Drug Application (NDA) for ARAKODA. This will facilitate a Phase IIb clinical study of SJ733 for Vivax malaria, combining SJ733 with a single dose of Tafenoquine.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 1:14 pm

Trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:55 pm

Trading for SXTP was halted at 7:50:00 p.m. ET due to pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 11:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.